Tirzepatide, sold as Mounjaro for type 2 diabetes in the United States, has become a major part of the public conversation about diabetes and metabolic health. Recent reporting has focused on two related developments: a large real-world study linking tirzepatide with fewer major cardiovascular events than a cardiovascular-neutral comparison medicine, and a new Mounjaro indication to reduce major cardiovascular risk in adults with type 2 diabetes at increased cardiovascular risk.
Both developments are significant. Neither means that tirzepatide is the right choice for every person with type 2 diabetes, that medication replaces the rest of cardiovascular care, or that individuals should change treatment based on a headline.
The most useful way to understand the news is to separate three questions: What did the randomized trial find? What did the real-world study find? And what does the current product label actually say?
What does the updated Mounjaro label say?
According to the current U.S. Mounjaro prescribing information, Mounjaro is indicated, alongside diet and exercise, to improve glycemic control in adults and pediatric patients age 10 years and older with type 2 diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events—cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke—in adults with type 2 diabetes who have increased cardiovascular risk.
That is an important regulatory development. It places cardiovascular risk reduction alongside glucose management as a labeled use for the diabetes brand of tirzepatide.
It does not mean that every adult with type 2 diabetes automatically needs Mounjaro. A labeled indication identifies an approved use; it does not replace individualized prescribing. Clinicians still need to consider cardiovascular and kidney history, glucose goals, other medications, side-effect risk, contraindications, access, cost, personal preferences, and the person’s broader care plan.
The randomized trial: noninferior to a medicine with established benefit
The core randomized cardiovascular-outcomes study is SURPASS-CVOT. In this trial, 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease were randomized to tirzepatide or dulaglutide, a GLP-1 receptor agonist with established cardiovascular benefit. Participants were followed for a median of about four years.
The primary outcome—a composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke—occurred in 12.2% of people assigned to tirzepatide and 13.1% of those assigned to dulaglutide. The reported hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01.
The trial met its prespecified criterion for noninferiority. In plain language, tirzepatide was shown not to be worse than dulaglutide on the primary cardiovascular outcome within the trial’s statistical framework. It did not establish superiority over dulaglutide.
That distinction is not a disappointment or a technical footnote. Dulaglutide is not a neutral comparison drug. It already has evidence of cardiovascular benefit. Demonstrating comparable performance to an established cardioprotective therapy gives clinicians meaningful information and patients another evidence-based option. But the result should not be simplified into “tirzepatide beat dulaglutide for heart protection.” It did not.
The real-world cohort study: a credible signal, not a causal verdict
A 2026 BMJ population-based cohort study evaluated 52,971 people aged 40 or older with type 2 diabetes, a body mass index of at least 25, and established atherosclerotic cardiovascular disease. The researchers compared people initiating tirzepatide with people initiating sitagliptin, a DPP-4 inhibitor chosen as a cardiovascular-outcome-neutral comparator or “placebo proxy.”
At one year, the weighted risk of the study’s major adverse cardiovascular event composite was 2.9% for tirzepatide and 4.4% for sitagliptin. The risk difference was −1.4 percentage points, the estimated hazard ratio was 0.68, and the study reported a number needed to treat of 70. The association appeared to be driven in part by lower myocardial infarction risk; ischemic-stroke risk did not differ meaningfully between the groups.
Those are notable findings, especially because the study examined real-world clinical practice rather than a narrowly selected clinical-trial population. The researchers used propensity-score overlap weighting, negative-control outcomes, and an approach benchmarked against randomized trials to reduce bias.
Still, it remains an observational study. People were not randomly assigned to treatment. Prescribing decisions may reflect health status, clinician preference, access, frailty, diabetes severity, patient motivation, or other factors that are difficult to capture fully in claims data. Sophisticated statistical methods can reduce confounding. They cannot remove every source of it.
The BMJ study provides a strong real-world association. It does not, by itself, prove that tirzepatide caused every observed reduction in cardiovascular events.
The study also reported lower infection-related outcomes in the tirzepatide group. That result is hypothesis-generating and should not be treated as an established reason to prescribe the medication. Unexpected benefits need confirmation and a clear biologic explanation.
Safety, suitability, and the importance of clinical guidance
Tirzepatide is a prescription medicine with important benefits and important limitations. The prescribing information carries a boxed warning concerning thyroid C-cell tumors and states that Mounjaro is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It also includes warnings and precautions related to severe gastrointestinal adverse reactions, pancreatitis, hypoglycemia when used with insulin or an insulin secretagogue, acute kidney injury due to volume depletion, gallbladder disease, diabetic retinopathy complications in some patients, and other concerns.
Common adverse effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. For some people, these effects are manageable. For others, they may limit use or require a different plan. The same label notes that oral contraceptive effectiveness may be reduced after starting Mounjaro and after dose escalation, requiring discussion of backup or alternative contraception for the periods specified in the prescribing information.
This is why treatment decisions should happen with a clinician who knows the individual’s medical history. It is especially important not to stop insulin or another glucose-lowering medication independently when starting a new therapy. Medication adjustments may be necessary, but they need clinical supervision to reduce risk of hypoglycemia, hyperglycemia, or other complications.
Heart health requires more than one medication decision
The updated indication and new studies are encouraging developments for people with type 2 diabetes and cardiovascular risk. But no medication can fully substitute for comprehensive care.
Cardiovascular risk is shaped by blood pressure, cholesterol, smoking, kidney health, glucose management, sleep, physical activity, food environment, stress, social support, medication adherence, and access to care. Medication can be a vital part of a risk-reduction plan. It may protect organs and reduce immediate risk while a person works on sustainable changes in daily life.
The mistake is not using medication. The mistake is treating medication as the whole story.
A durable plan might include cardiovascular and kidney screening, a food pattern that is practical and satisfying, regular movement suited to the person’s ability, sleep support, stress and mental-health care, smoking cessation if relevant, and regular medication review. It should also acknowledge real constraints such as cost, caregiving, work schedules, pain, and food access.
Diabetes Reversal Group believes type 2 diabetes care is strongest when it addresses the whole person—food, movement, sleep, stress, support systems, and ongoing clinical monitoring. For some people, clinician-directed medication is an important part of that plan; for everyone, lasting health requires more than a prescription alone.
By: Dr. Jeffrey Hockings, CEO/ Founder & Kristine Burke, MD, Chief Medical Officer
Do not start, stop, or change diabetes medication without guidance from the clinician managing your care.